Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2019 / Cilt: 29 - Sayı: 1

Prognostic Significance of Clinicopathological and Immunophenotypic Properties of Diffuse Large B Cell Lymphoma Patients

Diffüz Büyük B Hücreli Lenfomalı Hastaların Klinikopatolojik ve İmmünofenotipik Özelliklerinin Prognostik Önemi

Pages
62–66
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In our study, clinical and immunophenotypic features and significant prognostic parameters of DBBHLs were emphasized.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 30% of non-Hodgkin lymphoma (NHL) in adults.
📊
Key Findings & Data:Methods: The study included 43 patients with the diagnosis of DLBCL between 2009-2016.
💡
Conclusion & Impact:In our study, clinical and immunophenotypic features and significant prognostic parameters of DBBHLs were emphasized.
🔬Design:Research Article
📍Scope:2009-2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 30% of non-Hodgkin lymphoma (NHL) in adults. In our study, the clinicopathological features of patients with DLBCL were evaluated retrospectively. Methods: The study included 43 patients with the diagnosis of DLBCL between 2009-2016. Clinical and histopathological features of the patients were collected from the archive of our hospital. Results: The mean age of the patients was 62.5 (23-86) years. Twenty-four of them (55.8%) were male and 19 (44.2%) were female. Twenty- five patients (58.1%) had B symptoms. Early stage (I and II) disease was seen in 21 (48.8%) patients, while advanced stage (III and 1V) disease was seen in 22 (51.2%) patients. Bone marrow involvement was present in 5 (11.6%) patients. Nodal involvement was present in 39.5% and extranodal involvement in 60.5% of the patients. The most commen involved node was cervical lymph node and the most involved extranodal site was gastrointestinal system and especially stomach. Immunohistochemically, BCL2 and BCL6, which had prognostic significance, were expressed as 46.5% (n=20) and 27.9% (n=12) of the cases, respectively. A significant relationship was found between Bcl6 protein expression and gender (p<0.001, almost all female patients) and extranodal involvement (p=0.009). The patients were in a low risk group with a rate of 58.1% and a high risk of 41.9% according to the İnternational Prognostic Index (IPI). Twenty-seven out of 43 patients exited. The mean survival rate was 37.2 percent. Conclusion: In this study, there was no correlation between the histopathological features and mean life span, but an inverse relationship was found with IPI score. In our study, clinical and immunophenotypic features and significant prognostic parameters of DBBHLs were emphasized.

Özet

Amaç: Diffüz büyük B hücreli lenfoma (DBBHL), erişkinlerdeki non-Hodgkin lenfoma (NHL)’ların yaklaşık %30’unu oluşturur. Çalışmamızda, DBBHL tanısı alan hastaların klinikopatolojik özellikleri retrospektif olarak değerlendirilmiştir. Yöntem: Çalışmamızı 2009-2016 tarihleri arasında DBBHL tanısı verilen 43 hasta oluşturmaktadır. Hastalara ait klinik ve histopatolojik özellikler hastanemiz arşiv kayıtlarından toplandı. Bulgular: Hastaların ortalama yaşı 62,5 (23-86) olup, 24’ü (%55,8) erkek, 19’u (%44,2) kadındı. Yirmi beş hastada (%58,1) B semptomları vardı. Erken evre (I ve II) hastalık 21 (%48,8) hastada, ileri evre (III ve 1V) hastalık 22 (%51,2) hastada görüldü. Kemik iliği tutulumu 5 (%11,6) hastada vardı. Nodal tutulum %39,5 ve ekstranodal tutulum, hastaların %60,5’inde mevcuttu. Nodal olarak en sık servikal lenf nodu, ekstranodal olarak ise gastrointestinal sistem tutulmuştu. Gastrointestinal sistemden mide sık tutulum yeriydi. Olgularda immünohistokimyasal olarak prognostik önemi olan BCL2 ve BCL6, sırasıyla %46,5 (n=20) ve %27,9 (n=12) oranında eksprese oldu. Bcl6 protein ekspresyonu ile cinsiyet (p<0,001, hemen tümü kadın hasta) ve ekstranodal tutulum arasında anlamlı ilişki görüldü (p=0,009). Hastalar uluslararası prognostik endeks (IPI) göre %58,1 oranında düşük, %41,9 oranında yüksek risk grubunda idi. Kırk üç hastanın 27’si eks olmuştur. Ortalama yaşam oranı %37,2 idi. Sonuç: Bu çalışmada, hastaların histopatolojik özellikleri ile ortalama yaşam arasında bir ilişki saptanmazken, IPI skor ile ters bir ilişki saptanmıştır. Çalışmamızla DBBHL’ların klinikopatolojik ve immünofenotipik özellikleri ve prognostik önemi olan parametrelere dikkat çekilmiştir.

🔖

Cite This Article

KAHRAMAN, D. S., ÜNLÜ, A. G. D., CEYLAN, C. (2019). Prognostic Significance of Clinicopathological and Immunophenotypic Properties of Diffuse Large B Cell Lymphoma Patients. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 29 - Sayı: 1, 62–66. https://ajindex.com/articles/193586

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Gogia A, Das CK, Kumar L, Sharma A, Tiwari A, Sharma MC, and Mallick S. Diffuse large B-cell lymphoma: An institutional analysis South Asian J Cancer. 2018 Jul-Sep;7(3):200-2.
  2. Nimmagadda RB, Digumarti R, Nair R, et al. Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from India. Indian J Med Paediatr Oncol. 2013;34:299-304. González-Barca E, Coronado M, Martín A, et al and on behalf of the Spanish Lymphoma Group (GELTAMO). Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma. Oncotarget. 2018 Aug 17;9(64):32383-99.
  3. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-90.
  4. Prakash G, Sharma A, Raina V, et al. Bcell non-Hodgkin’s lymphoma: Experience from a tertiary care cancer center. Ann Hematol. 2012;91:1603-11.
  5. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, and Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87:146-71.
  6. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
  7. Sharma M, Mannan R, Madhukar M, et al. Immunohistochemical (IHC) Analysis of Non-Hodgkin’s Lymphoma (NHL) Spectrum According to WHO/REAL Classification: A Single Centre Experience from Punjab, IndiaJ Clin Diagn Res. 2014 Jan;8(1):46-9.
  8. Mushtaq S, Akhtar N, Jamal S, et al. Malignant lymphomas in Pakistan according to the WHO classification of lymphoid neoplasms. Asian Pac J Cancer Prev. 2008;9(2):229-32.
  9. Boussios S, Zerdes I, Vassou A, et al. Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literatüre. Hematol Rep. 2018 Mar 2;10(1):7070. Wang C, Yuan C, He H, Bai O. Clinicopathological features and prognostic analysis of 151 patients with primary extranodal non-Hodgkin’s lymphoma. Zhonghua Zhong Liu Za Zhi. 2014 Nov;36(11):858-62.
  10. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74-87.
  11. Nagi AH, Al Minawy L, Naseem N, Henna SN, Naveed IA. A study of the morphological patterns of extranodal nonHodgkin lymphoma in Pakistani and Saudi populations. Biomedica. 2010;26:118-23.
  12. Yoon SO, Suh C, Lee DH, et al. Distribution of lymphoid neoplasms in the Republic of Ko